79 related articles for article (PubMed ID: 1808414)
21. Results and further perspectives of plasmocytoma chemotherapy.
Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
[TBL] [Abstract][Full Text] [Related]
22. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
23. [Interferon in the treatment of multiple myeloma].
Kuzmits R; Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Flener R; Scheithauer W
Acta Med Austriaca; 1985; 12(5):135-8. PubMed ID: 3914174
[TBL] [Abstract][Full Text] [Related]
24. [The blood rheological indices of patients with necrobiosis lipoidica].
Petrova GA; Levin GIa
Vestn Dermatol Venerol; 1989; (12):45-8. PubMed ID: 2633553
[TBL] [Abstract][Full Text] [Related]
25. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
26. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
27. Disturbances of platelet function in patients with multiple myeloma.
Czestochowska E; Tymiński W; Górski J; Umiastowski J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):845-51. PubMed ID: 2453414
[TBL] [Abstract][Full Text] [Related]
28. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
[TBL] [Abstract][Full Text] [Related]
29. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Tarella C; Boccadoro M; Omedé P; Bondesan P; Caracciolo D; Frieri R; Bregni M; Siena S; Gianni AM; Pileri A
Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and laboratory analysis of the cases of multiple myeloma with over 5-year survival time from the beginning of the antineoplastic treatment].
Kraj M; Rostkowska J; Sokołowska U; Maj S
Acta Haematol Pol; 1991; 22(1):42-7. PubMed ID: 1823966
[TBL] [Abstract][Full Text] [Related]
31. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
32. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
33. [Rheologic and hemocoagulation parameters in patients with multiple myeloma during therapy].
Bessmel'tsev SS; Katsadze IuL; Abdulkadyrov KM; Zamotina TB
Gematol Transfuziol; 1992 Mar; 37(3):19-23. PubMed ID: 1516794
[No Abstract] [Full Text] [Related]
34. Red cell deformability in patients with cerebral vasospasm.
Sakai T; Okada J; Hara M; Ogashiwa M; Takeuchi K
Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):79-82. PubMed ID: 3988398
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
36. [Acute and chronic renal failure in patients with myeloma].
Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV
Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869
[TBL] [Abstract][Full Text] [Related]
37. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
Paule B; Quillard J; Bisson M; Massias P
Nouv Rev Fr Hematol (1978); 1987; 29(6):391-6. PubMed ID: 2454453
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
39. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
40. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
